TTY Biopharm

Name

TTY Biopharm

Legal name

TTY Biopharm Company Limited

Website

https://eng.tty.com.tw

Company type

Public

Founded year

1960

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Specialty pharmaceuticals
• Drug delivery technology
• Oncology therapeutics
• Anti-infective medicines
• Contract manufacturing

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: TTY generates revenue primarily through the sale of branded generic pharmaceuticals in Taiwan and international markets, including oncology drugs (TOT), anti-infective products (TIT), and healthcare products (KAM).
2. CDMO/Contract Manufacturing Services: TTY offers Contract Development and Manufacturing services leveraging its PIC/S GMP certified facilities for clinical supply and commercial production.
3. Licensing and Royalty Revenue: TTY receives licensing revenue including upfront payments, regulatory milestones, and supply of drug product at percentage of net selling price from partners such as PAION for remimazolam.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

Core offering

TTY Biopharm develops, manufactures, and sells branded generic pharmaceutical products across three therapeutic divisions: Oncology (TOT), Anti-Infection (TIT), and Healthcare (KAM), sold primarily to hospitals and medical centers in Taiwan and select Asian markets. The company applies proprietary liposome and microsphere drug delivery technologies, supported by PIC/S GMP certified manufacturing facilities, and supplements its own portfolio with CDMO services and international licensing partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• TS-1 Capsule Oral anti-cancer drug (tegafur/gimeracil/oteracil combination) licensed from Taiho Pharmaceutical for development and marketing in Taiwan; used to treat gastric cancer, colorectal cancer, NSCLC, pancreatic cancer, biliary tract cancer, and metastatic breast cancer, available through hospital oncology departments.
• Yondelis (trabectedin) Marine-derived anticancer drug (trabectedin) licensed from PharmaMar for distribution in Taiwan, Hong Kong, and Macao; approved for soft tissue sarcoma in Taiwan and recurrent ovarian cancer in Hong Kong, supplied to hospital oncology units.
• Remimazolam Ultra-short-acting intravenous benzodiazepine sedative licensed from PAION AG for development and commercialization in Taiwan; used for procedural sedation during invasive medical procedures such as colonoscopy and bronchoscopy, marketed to hospitals and procedural settings.
• Broad-spectrum antibacterial (Everest Medicines) Broad-spectrum antibacterial for treatment of complicated intra-abdominal infections including MDRO/Superbug infections, licensed from Everest Medicines for exclusive commercialization in Taiwan; intended for hospital infectious disease and ICU use.
• Brosym Anti-infective injection product within TTY's Anti-Infection (TIT) division, marketed to hospitals for antibiotic therapy.
• Lipo-AB Liposomal anti-infective product within TTY's Anti-Infection (TIT) division leveraging TTY's proprietary liposome drug delivery platform; supplied to hospital infectious disease and intensive care teams.
• CDMO / Contract Development and Manufacturing Services Contract Development and Manufacturing services leveraging TTY's PIC/S GMP certified facilities and specialized liposome/microsphere technologies for clinical supply and commercial production of cytotoxic and non-cytotoxic pharmaceutical products; sold to pharmaceutical companies.
• PIC/S GMP Business Service GMP-certified manufacturing service for cytotoxic and non-cytotoxic pharmaceutical products offered through TTY's PIC/S GMP compliant facilities (Chungli, Lioudu, Neihu factories); sold to pharmaceutical partners needing certified production capacity.
• Licensing services Licensing arrangement enabling international pharmaceutical partners (e.g., PAION, PharmaMar, Taiho, Everest Medicines) to develop, manufacture, and commercialize drugs via TTY for Taiwan and other covered territories, generating upfront payments, milestones, royalties, and supply revenue.

Quantifiable outcome

• Top 1% of largest biopharmaceutical companies in Taiwan in oncology and critical infection fields
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Taiho Pharmaceutical: Taiho is the originator and licensor of TS-1 to TTY and is a Japan-based specialty oncology pharmaceutical company with comparable focus on oral cytotoxic and supportive oncology agents. Comparable along therapeutic area (oncology), portfolio composition (oral cytotoxics, antibody-derived agents), and CDMO-era specialization.
• Yung Shin Pharmaceutical Industrial: One of Taiwan's largest domestic pharmaceutical manufacturers with branded generics, injectables, and contract manufacturing. Directly comparable along geography (Taiwan), therapeutic breadth (oncology, anti-infectives, healthcare), and GMP manufacturing footprint.
• Standard Chemical & Pharmaceutical: Taiwan-listed specialty pharmaceutical company with branded generics, complex formulations, and hospital-channel distribution. Comparable along Taiwan-domestic branded generics, hospital-focused GTM, and specialty injectables.
• Center Laboratories: Taiwan-based pharmaceutical manufacturer with branded injectables, sterile manufacturing, and PIC/S GMP capability. Comparable along Taiwan footprint, sterile injectable manufacturing, and branded product orientation.
• PharmaEssentia Corporation: Taiwan-listed specialty biopharmaceutical company focused on oncology and hematology with proprietary technology platform. Comparable along Taiwan base, oncology specialty focus, and platform-driven branded specialty pipeline.

Emerging players

• PharmaMar: Spanish biopharmaceutical company focused on marine-derived oncology (Yondelis, Zepzelca). Comparable as TTY's Yondelis licensor and similarly positioned as a mid-sized specialty oncology company with marine-derived and innovative cytotoxic assets.
• OBI Pharma: Taiwan-listed clinical-stage oncology biopharmaceutical company developing novel ADCs and cancer therapeutics. Comparable along Taiwan base and oncology focus, though OBI is more R&D-stage whereas TTY has commercialized specialty oncology revenue.

Broad incumbents

• Yuhan Corporation: Korean diversified pharmaceutical company with branded specialty, generics, CDMO partnerships, and established Asia-Pacific distribution. Comparable along Asian specialty pharma scale, branded generics model, and CDMO/in-licensing strategy across oncology and anti-infectives.
• Daiichi Sankyo: Japan-headquartered global pharmaceutical leader with major oncology franchise including cytotoxic and ADC platforms. Comparable along oncology specialty focus, Asia-Pacific branded specialty distribution, and liposomal/injectable technology overlap.
• AstraZeneca Asia-Pacific: Global pharmaceutical major with extensive oncology, anti-infection, and specialty portfolio across Asia-Pacific. Comparable as the incumbent competitive set for hospital-channel oncology and anti-infective business in Taiwan and Southeast Asia where TTY operates.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tty-biopharm

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TTY Biopharm